GlassScriptPhysician profile
Flavio H Alvarez
NPI 1932175601
$10,434.02
in general payments reported to CMS, 2019-2025
37 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $165 · 2021: $978 · 2022: $2,919 · 2023: $1,612 · 2024: $2,100 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,176.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,521.93 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,548.11 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $680.60 | 2019-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $673.06 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $625.01 | 2021-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $608.02 | 2019-2025 | Rayaldee |
| Amgen INC. | $516.34 | 2019-2025 | Tavneos, Krystexxa |
| Fresenius USA INC. | $250.00 | 2021 | |
| Travere Therapeutics, INC. | $246.96 | 2022-2025 | |
| Novo Nordisk INC | $230.80 | 2024-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $197.29 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $189.53 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $188.74 | 2024 | Xphozah 30 Mg, Ibsrela |
| Novartis Pharmaceuticals Corporation | $185.52 | 2019-2025 | |
| Akebia Therapeutics INC | $173.04 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $156.50 | 2022-2024 | Terlivaz, Acthar |
| Venturemed Group, INC. | $152.87 | 2024 | Flex Vessel Prep System |
| Glaxosmithkline, LLC. | $150.12 | 2021-2025 | Benlysta, Jesduvroq |
| Bard Peripheral Vascular, INC. | $140.61 | 2019 | |
| Medtronic, INC. | $136.21 | 2023 | Ellipsys Vascular Access System |
| Vifor Pharma, INC. | $107.86 | 2020-2023 | Veltassa, Korsuva |
| Genzyme Corporation | $101.46 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.54 | 2023-2025 | Jardiance, Tradjenta |
| Baxter Healthcare | $94.44 | 2019 | |
| Cormedix INC. | $87.60 | 2024 | Defencath |
| Ultragenyx Pharmaceutical INC. | $59.35 | 2019-2023 | Crysvita |
| Apellis Pharmaceuticals, INC. | $57.89 | 2025 | |
| Ani Pharmaceuticals, INC. | $54.65 | 2024-2025 | Purified Cortrophin Gel |
| Veloxis Pharmaceuticals, INC. | $37.68 | 2025 | Envarsus |
| Outset Medical INC | $28.68 | 2021 | |
| Nxstage Medical, INC. | $26.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.59 | 2021 | |
| Daiichi Sankyo INC. | $21.50 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.17 | 2023 | Soliris |
| Shield Therapeutics INC | $20.11 | 2025 | |
| Amag Pharmaceuticals, INC. | $14.91 | 2019 | |
| Allergan, INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flavio Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.